Literature DB >> 10938095

Class II transactivator: mastering the art of major histocompatibility complex expression.

J A Harton1, J P Ting.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10938095      PMCID： PMC86093          DOI： 10.1128/MCB.20.17.6185-6194.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN： 0270-7306            Impact factor:   4.272


× No keyword cloud information.
  151 in total

Review 1.  The immunology of pregnancy.

Authors:  A P Weetman
Journal:  Thyroid       Date:  1999-07       Impact factor: 6.568

2.  Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guérin involves class II transactivator and depends on the Nramp1 gene.

Authors:  W Wojciechowski; J DeSanctis; E Skamene; D Radzioch
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

Review 3.  HLA class II transgenic mice as models of human diseases.

Authors:  V Taneja; C S David
Journal:  Immunol Rev       Date:  1999-06       Impact factor: 12.988

4.  Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.

Authors:  Y Itoh-Lindstrom; J F Piskurich; N J Felix; Y Wang; W J Brickey; J L Platt; B H Koller; J P Ting
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

5.  Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription.

Authors:  A K Tai; G Zhou; K Chau; S J Ono
Journal:  Mol Immunol       Date:  1999-05       Impact factor: 4.407

6.  Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction.

Authors:  Y Lu; J M Boss; S X Hu; H J Xu; G Blanck
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

7.  GTP binding by class II transactivator: role in nuclear import.

Authors:  J A Harton; D E Cressman; K C Chin; C J Der; J P Ting
Journal:  Science       Date:  1999-08-27       Impact factor: 47.728

8.  Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.

Authors:  H T Lu; J L Riley; G T Babcock; M Huston; G R Stark; J M Boss; R M Ransohoff
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

9.  The chicken beta 2-microglobulin gene is located on a non-major histocompatibility complex microchromosome: a small, G+C-rich gene with X and Y boxes in the promoter.

Authors:  P Riegert; R Andersen; N Bumstead; C Döhring; M Dominguez-Steglich; J Engberg; J Salomonsen; M Schmid; J Schwager; K Skjødt; J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

10.  CIITA activates the expression of MHC class II genes in mouse T cells.

Authors:  C H Chang; S C Hong; C C Hughes; C A Janeway; R A Flavell
Journal:  Int Immunol       Date:  1995-09       Impact factor: 4.823
View more
  70 in total

1.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.

Authors:  M W Linhoff; J A Harton; D E Cressman; B K Martin; J P Ting
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

2.  Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.

Authors:  G Li; J A Harton; X Zhu; J P Ting
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

3.  Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.

Authors:  Krzysztof Masternak; Walter Reith
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

4.  CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II.

Authors:  Charalambos Spilianakis; Androniki Kretsovali; Theodora Agalioti; Takis Makatounakis; Dimitris Thanos; Joseph Papamatheakis
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

5.  Novel functions for TAF7, a regulator of TAF1-independent transcription.

Authors:  Ballachanda N Devaiah; Hanxin Lu; Anne Gegonne; Zeynep Sercan; Hongen Zhang; Robert J Clifford; Maxwell P Lee; Dinah S Singer
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

6.  New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.

Authors:  Michal Krawczyk; Krzysztof Masternak; Madeleine Zufferey; Emmanuèle Barras; Walter Reith
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

7.  An MHC class II restriction bias in CD4 T cell responses toward I-A is altered to I-E in DM-deficient mice.

Authors:  Paula R Menges; Scott A Jenks; Elizabeth K Bikoff; David R Friedmann; Zackery A G Knowlden; Andrea J Sant
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

8.  CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression.

Authors:  Lisa M Rimsza; Wing C Chan; Randy D Gascoyne; Elias Campo; Elaine S Jaffe; Louis M Staudt; Jan Delabie; Andreas Rosenwald; Shawn P Murphy
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

9.  Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP.

Authors:  Meghan Bushway; Kelly A Cycon; Kathleen Mulvaney; Shawn P Murphy
Journal:  Immunogenetics       Date:  2009-12-19       Impact factor: 2.846

Review 10.  Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-07       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.